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Atopic dermatitis exacerbated with ustekinumab in a psoriatic patient
with childhood history of atopyDear Editor,
Ustekinumab is a biological agent that is currently approved for
the treatment of moderate to severe plaque psoriasis. It is a mono-
clonal antibody that binds the p40 subunit of IL-12 and IL-23 to
limit the progression of the Th1 and Th17 inﬂammatory immune
responses. Recently, it has been suggested that ustekinumab could
represent a potential treatment for atopic dermatitis (AD).1e3 How-
ever, inadequate response to ustekinumab in AD patients has also
been reported.4 We present a case of paradoxically exacerbated
AD during the ustekinumab treatment for psoriasis.
A 21-year-old man with a 7 year history of severe psoriasis re-
fractory to conventional systemic treatments and childhood history
of atopy (atopic dermatitis-AD, asthma, seasonal rhinitis) was
treated with ustekinumab. The patient was without major symp-
toms from respiratory system and AD lesions within a period of 5
years before the date of starting the treatment. He was taking mon-
telukast, antihistamines, inhaled corticosterois and formoterol for
asthma. Psoriatic lesions and no clinical sings of AD were found
on baseline examination (Fig. 1). Ustekinumab 45 mg (1 injection
at week 0 and week 4, then every 12 weeks) was introduced (ac-
cording to body weight: 76 kg). After 18 months and following
excellent results, the patient decided to discontinue therapy. But
8 months later recurrence of psoriasis was observed and ustekinu-
mab was restarted. The baseline PASI fell from 11,4 to 3,0 after 4
weeks of treatment with ustekinumab, complete remission of pso-
riasis was achieved after 8 weeks of therapy. However, intense
generalized itching occurred since the ﬁrst dose was administered.
Severe AD appeared on the neck and lower limbs about 6 weeks af-
ter the reintroduction of ustekinumab (Fig. 2). Eczematous drug
eruption and AD exacerbation due to stress, infection, or other
external factors (i.e. topical treatments of psoriasis) was excluded
in the differential diagnosis. Apart from dermatologic ﬁndings,
physical examination revealed no abnormalities. Laboratory tests
showed peripheral blood eosinophilia (1,48  109/L, compared to
the baseline of 0,46  109/L, to the 16 weeks of 0,58  109/L, to
the 28 weeks of ustekinumab therapy of 0,67  109/L, and to the
recurrence of psoriasis of 0,66  109/L), as well as abnormal in-
crease in serum allergen-speciﬁc immunoglobulin E (sIgE) level
including dog-, cat-, hamster-, and grass pollen-speciﬁc IgE. Total
IgE level was 12576 IU/ml (0e100,0 IU/l reference range). Other lab-
oratory data (erythrocyte sedimentation rate, C-reactive protein
level, complete blood count, biochemical parameters of liver and
kidney, urinalysis) were normal at several time points. SpirometryPeer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).revealed normal pulmonary function, fractional exhaled nitric ox-
ide (FeNo) level was low (24 ppb) pointing to the well-controlled
asthma (FeNo values range from 22 to 44 ppb). Ustekinumab was
stopped again, improvement of AD was achieved after the adminis-
tration of the short course of systemic prednisone at 40mg daily for
6 days followed by 20 mg for 4 days and 10 mg for 4 days. Topical
corticosteroid therapy was needed to control the disease. While
psoriasis was stable no complete remission of AD and no reduction
of peripheral eosinophilia (1.63  109/L) was observed during 12-
months follow up. The biologic had no impact for the asthma
course.
Our case is particularly interesting because it describes a patient
with remission of psoriasis and ﬂare of AD due to ustekinumab
therapy. To our knowledge, ustekinumab has not been reported
to exacerbate AD. The patient previous has been treated for 18
month without any ﬂare suggesting the eczematous drug eruptionFig. 1. Psoriatic lesions on the head before the initiating ustekinumab therapy.
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Fig. 2. Skin lesions corresponding to atopic dermatitis on the lower limbs after the
reintroduction of ustekinumab for psoriasis relapse.
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apy is interrupted followed by a second exposure. Some authors
have described patients with an eczematous eruption that
appeared after the administration of ustekinumab.5,6 However,
the eczema has lasted during 12-months follow up after the ﬁnal
dose of ustekinumab, supporting the diagnosis of AD in our patient.
Why ustekinumab has exacerbated AD but not psoriasis para-
doxically is hard to explain. It is uncommon for AD to coexist
with psoriasis.7 Both diseases have distinct genetic mechanisms
with opposing effects in shared pathways inﬂuencing epidermal
differentiation and immune response.8 Psoriasis is believed to be
mediated by Th1/Th17 cells and AD by Th2/Th22 cells.9 The Th17
axis is also activated in patients with acute AD and plays some
role in the pathogenesis of the disease.9 Therefore, ustekinumab
could represent a potential treatment for AD. However, this biologic
blocking Th1 inﬂammatory pathways (IL-12) partially acts as TNF-a
inhibitor and possibly this may result in downregulation of Th1cytokines and manifestation of Th2-associated disease.10 Increased
Th2 activity in the presented patient might has resulted in the pe-
ripheral blood eosinophilia after initiating ustekinumab. Subse-
quently, AD-like skin lesions were induced by the therapy
reintroduction. Therefore, we would like to highlight the possible
connection between the treatment with ustekinumab and the ﬂare
of AD, while psoriasis go into remission.
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